# Clinical Use of Pathogen Reduced Red Blood Cell Suspension

> **NCT03426553** · PHASE3 · COMPLETED · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 50 (actual)

## Conditions studied

- Oncologic Disorders
- Hematologic Diseases

## Interventions

- **BIOLOGICAL:** Riboflavin+UV RBC
- **BIOLOGICAL:** irradiated RBC

## Key facts

- **NCT ID:** NCT03426553
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-15
- **Primary completion:** 2018-09-17
- **Final completion:** 2018-12-17
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03426553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03426553, "Clinical Use of Pathogen Reduced Red Blood Cell Suspension". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03426553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*